A Phase 2b Study of IMVT-1402 in CIDP
Research type
Research Study
Full title
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
IRAS ID
1011913
Contact name
Dylan Hernandez
Contact email
Sponsor organisation
Immunovant Sciences GmbH
Clinicaltrials.gov Identifier
Research summary
In CIDP, the body produces abnormal antibodies against its own nerves and attacks them. As a result, muscles are weaker and get tired more quickly than normal.
This study will test a new treatment for CIDP, called IMVT-1402, that works by reducing the level of antibodies, including these abnormal antibodies. This treatment might keep CIDP under control better than current treatments (like immunoglobulin [Ig] or corticosteroids).
This study will test how well IMVT-1402 treatment works for CIDP. The study will compare IMVT-1402 to a placebo.
Researchers will do checkups to see how well the study treatment works. This study has 4 parts:
Screening period
Period 1: A 24-week main treatment period in which participants will either take 600mg of IMVT-1402 or placebo once a week
Period 2: An optional 52-week treatment period in which all participants will take 600m of IMVT-1402 once a week
Safety follow-up: Participants will not take any study treatment
Potential participants can enter the study if they meet certain eligibility criteria.REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
25/NE/0129
Date of REC Opinion
14 Aug 2025
REC opinion
Further Information Favourable Opinion